Extracellular vesicle

Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are naturally released from a cell and, unlike a cell, cannot replicate. EVs range in diameter from near the size of the smallest physically possible unilamellar liposome (around 20-30 nanometers) to as large as 10 microns or more, although the vast majority of EVs are smaller than 200 nm. They carry a cargo of proteins, nucleic acids, lipids, metabolites, and even organelles from the parent cell. Most cells that have been studied to date are thought to release EVs, including some bacterial, fungal, and plant cells that are surrounded by cell walls. A wide variety of EV subtypes have been proposed, defined variously by size, biogenesis pathway, cargo, cellular source, and function, leading to a historically heterogenous nomenclature including terms like exosomes and ectosomes.

Numerous functions of EVs have been established or postulated. The first evidence for the existence of EVs was enabled by the ultracentrifuge, the electron microscope, and functional studies of coagulation in the mid-20th century. A sharp increase in interest in EVs occurred in the first decade of the 21st century following the discovery that EVs could transfer nucleic acids such as RNA from cell to cell. Associated with EVs from certain cells or tissues, nucleic acids could be easily amplified as markers of disease and also potentially traced back to a cell of origin, such as a tumor cell. The discovery also implied that EVs could be used for therapeutic purposes, such as delivering nucleic acids or other cargo to diseased tissue. This growing interest was paralleled by formation of companies and funding programs focused on development of EVs as biomarkers or therapies of disease, the founding of an International Society for Extracellular Vesicles (ISEV), and establishment of a scientific journal devoted to the field, the Journal of Extracellular Vesicles.

Background/History

Evidence for the existence of EVs and their functions was first gathered by combined applications of ultracentrifugation, electron microscopy, and functional studies during the mid-20th century.[1] Ultracentrifuged pellets from blood plasma were reported to have procoagulant properties by Erwin Chargaff and Randolph West in 1946.[2] The platelet derivation and lipid-containing nature of these particles was further articulated by Peter Wolf.[3] Around the same time, H. Clarke Anderson and Ermanno Bonucci separately described the calcifying properties of EVs in bone matrix.[4][5]

Although the extracellular and vesicular properties of EVs had been recognized by numerous groups by the 1970s, the term “extracellular vesicle” was first used in a manuscript title in 1971.[5] This electron microscopy study of the flagellate freshwater alga 'Ochromonas danica' reported release of EVs from membranes including those of flagella. Soon thereafter, EVs were seen to be released from follicular thyroid cells of the bat during arousal from hibernation, suggesting the possible involvement of EVs in endocrine processes.[6] Reports of EVs in intestinal villi samples and, for the first time, in material from human cancer (adenoma)[7][8][9][10] referred back to even earlier publications that furnished similar evidence, although conclusions about EV release had not then been drawn. EVs were also described in bovine serum and cell culture conditioned medium[10][9] with distinctions made between “vesicles of the multivesicular body” and “microvesicles.”[10][1] These studies further noted the similarities of EVs and enveloped viruses.

In the early- to mid-1980s, the Stahl and Johnstone labs forged a deeper understanding of the release of EVs from reticulocytes[11][12][13], while progress was also made on EVs shed from tumor cells.[14][1] The reticulocyte research, in particular, showed that EVs could be released not only from the plasma membrane or surface of the cell, but also by fusion of the multivesicular body with the plasma membrane. During this time, EVs were described by many names, sometimes in the same manuscript, such as "shedding vesicles," "membrane fragments," "plasma membrane vesicles," "micro-vesicles/microvesicles," "exosomes," (previously used for mobile, transforming DNA elements in model organisms Drosophila and Neurospora[15][16]), "inclusion vesicles," and more, or referred to by organ of origin, such as "prostasomes" that were found to enhance sperm motility in semen.[17][1]

The involvement of EVs in immune responses became increasingly clear in the 1990s with findings of the group of Graça Raposo and others.[18][1] A clinical trial of dendritic cell-derived EVs was performed in France just before the turn of the century. Cells of the immune system were found capable of transferring transmembrane proteins via EVs. For example, the HIV co-receptors CCR5 and CXCR4 could be transferred from an HIV-susceptible cell to a refractory cell by "microparticles," rendering the recipient cell permissive to infection.[19][20]

Beginning in 2006, several laboratories reported that EVs contain nucleic acids and have the ability to transfer them from cell to cell.[21][22][23][24][25][26][1] Some RNAs were even found to be function in the recipient cell. Whether carrying RNA, surface molecules, or other factors, the involvement of EVs in cancer progression aroused considerable interest,[27] leading to hypotheses that specific EVs could target specific cells due to "codes" displayed on their surface;[28] create or enhance a metastatic niche;[29] betray the presence of specific cancers;[30] or be used as a therapy to target cancer cells.[31] Meanwhile, strides were made in the understanding of vesicle biogenesis and subtypes.[32][33][34][35]

Rapid growth of the EV research community in the early 2000s led to the creation of the International Society for Extracellular Vesicles (ISEV), which has led efforts for rigor and standardization in the field including establishment of the Journal of Extracellular Vesicles. A plethora of national and regional EV societies have also been formed. In 2012, the Director’s Office of the US National Institutes of Health (NIH) announced a program for funding of EV and extracellular RNA studies, the Extracellular RNA Communication Consortium (ERCC),[36] which subsequently invested >USD 100 million in EV research. A second round of funding was announced in 2018. Commercial investment in EV diagnostics and therapeutics also grew during this time. Exosome Diagnostics has developed several cancer diagnostic assays based in part on EV RNA. Codiak Biosciences is a company with intellectual property in the pancreatic cancer space.

Biogenesis and nomenclature

Diverse EV subtypes have been proposed, with names such as ectosomes, microvesicles, microparticles, exosomes, oncosomes, apoptotic bodies, and more.[1] These EV subtypes have been defined by various, often overlapping, definitions, based mostly on biogenesis (cell pathway, cell or tissue identity, condition of origin).[37] However, EV subtypes may also be defined by size, constituent molecules, function, or method of separation. Because of the bewildering and sometimes contradictory definitions of different EV subtypes, the current scientific consensus is that “extracellular vesicle” and variations thereon are the preferred nomenclature unless specific biogenetic origin can be demonstrated.[37] Subtypes of EVs may be defined by:

"a) physical characteristics of EVs, such as size (“small EVs” (sEVs) and “medium/large EVs” (m/lEVs), with ranges defined, for instance, respectively, <100nm or <200nm [small], or >200nm [large and/or medium]) or density (low, middle, high, with each range defined); b) biochemical composition (CD63+/CD81+- EVs, Annexin A5-stained EVs, etc.); or c) descriptions of conditions or cell of origin (podocyte EVs, hypoxic EVs, large oncosomes, apoptotic bodies)."[37]

Ectosomes/microvesicles/microparticles (plasma membrane origin)

The terms “ectosome,” “microvesicle” (MV), and “microparticle” (MP) refer to particles released from the surface of cells. Especially in the field of platelet research, MP has been the standard nomenclature. Formation of ectosomes may in some cases result from directed processes, and in others from shear forces or adherence of the PM to a surface.

Exosomes (endosomal origin)
Main article: Exosome (vesicle)

Exosome biogenesis begins with pinching off of endosomal invaginations into the multivesicular body (MVB), forming intraluminal vesicles (ILVs). If the MVB fuses with the plasma membrane, the ILVs are released as "exosomes." The first publication to use the term "exosome" for EVs presented it as a synonym for “micro-vesicle.”[38] The term has also been used for EVs within specific size ranges, EVs separated using specific methods, or even all EVs.

Apoptotic bodies

Apoptotic bodies are EVs that are released by dying cells undergoing apoptosis. Since apoptotic cells tend to display phosphatidylserine (PS) in the outer bilayer of the cell membrane, apoptotic bodies tend to externalize PS, although other EVs may also do so. Apoptotic bodies may be quite large (microns in diameter) but may also measure in the submicron range.

Large oncosomes, exophers, and other very large EVs

In addition to the very large EVs released during apoptosis, micron-sized EVs may be produced by cancer cells, neurons, and other cells. When produced by cancer cells, these particles are termed “large oncosomes”[39][40] and may reach 20 microns or more in diameter. These large EVs are practically cells except without full nuclei. They contain a functional cytoskeleton and energy sources (mitochondria), and may be motile, contributing to metastasis. Another class of large EV has been observed in neurons of the model organism C. elegans.[41] When injected with a dye, neurons were observed to sequester the dye into a portion of the cell and release it in a large EV dubbed the “exopher.”[41] This body was hypothesized to be a mechanism for disposal of unwanted cellular material. Technically, the platelets of certain vertebrates (which bud from megakaryocytes), as well as red blood cells (e.g., of adult humans) also fulfill the consensus definition of EVs.[37]

Enveloped viruses

Enveloped viruses are a type of EV produced under the influence of viral infection. That is, the virion is composed of cellular membranes but contains proteins and nucleic acids produced from the viral genome. Some enveloped viruses can infect other cells even without a functional virion, when genomic material is transferred via EVs. Certain non-enveloped viruses may also reproduce with assistance from EVs.[42]

Exomeres

The “exomere” is a recently discovered particle type that may be related to EVs.[43][44] in the size range of small EVs (as separated by asymmetric flow field-flow fractionation), the relationship of exomeres to EVs remains to be elucidated.

EV separation and concentration

Studying EVs and their cargo typically requires separation from a biological matrix (such as a complex fluid or tissue) so that the uniquely EV components can be analyzed. Many approaches have been used, including differential ultracentrifugation, density gradient ultracentrifugation, size exclusion chromatography, ultrafiltration, and affinity/immunoaffinity capture methods.[37][45][1][44] Each method has its own recovery and purity outcomes: that is, what percentage of input EVs are obtained, and the ratio of “true” EV components to co-isolates. EV separation can also be influenced by pre-analytical variables.[46][47][48]

EV characterization

Population-level EV analysis

Separated or concentrated populations of EVs may be characterized by several means. Total concentration of molecules in categories such as protein, lipid or nucleic acid. Total particle counts in a preparation can also be estimated, for example by light-scattering techniques. Each measurement technology may have a specific size range for accurate quantitation, and very small EVs (<100 nm diameter) are not detected by many technologies. Molecular “fingerprints” of populations can be obtained by “omics” technologies like proteomics, lipidomics, and RNomics, or by techniques like Raman spectroscopy. Overall levels of unique molecules can also be measured in the population, such as tetraspanins, phosphatidylserine, or species of RNA. It has been proposed that purity of an EV preparation can be estimated by examining the ratio of one population-level measurement to another, e.g., the ratio of total protein or total lipid to total particles.

Single-particle analysis

Specialized methods are needed to study EVs at the single particle level. The challenge for any putative single-particle method is to identify the individual EV as a single, lipid-bilayer particle, and to provide additional information such as size, surface proteins, or nucleic acid content. Methods that have been used successfully for single-EV analysis include optical microscopy and flow cytometry (for large EVs, usually >200 nm), electron microscopy (no lower bound), single-particle interferometric reflectance imaging (down to about 40 nm), and nano-flow cytometry (also to 40 nm). Some technologies allow the study of individual EVs without extensive prior separation from a biological matrix: to give a few examples, electron microscopy and flow cytometry.

Enriched and depleted markers

To demonstrate the presence of EVs in a preparation, as well as the relative depletion of non-EV particles or molecules, EV-enriched 'and' -depleted markers are necessary:[49] For example, the MISEV2018 guidelines recommend:

At least one membrane-associated marker as evidence of the lipid bilayer (e.g., a tetraspanin protein)
At least one cytoplasmic but ideally membrane-associated marker to show that the particle is not merely a membrane fragment
At least one “negative” or “depleted” marker: a “deep cellular” marker, a marker of a non-EV particle, or a soluble molecule not thought to be enriched in EVs.[37]

Usually, but not necessarily, the EV-enriched or -depleted markers are proteins that can be detected by Western blot, ELISA, mass spectrometry, or other widely-available methods. Assaying for depleted markers is thought to be particularly important, as otherwise the purity of an EV preparation cannot be claimed. However, most studies of EVs prior to 2016 did not support claims of the presence of EVs by showing enriched markers, and <5% measured the presence of possible co-isolates/contaminants.[50] Despite the high need, a list of EV contaminants is not yet available to the EV research community. A recent study suggested density-gradient-based EV separation from biofluids as an experimental set-up to compile a list of contaminants for EV, based upon differential analysis of EV-enriched fractions versus soluble protein-enriched fractions[51]. Soluble proteins in blood, the Tamm-Horsfall protein (uromodulin) in urine, or proteins of the nucleus, Golgi apparatus, endoplasmic reticulum, or mitochondria in eukaryotic cells. The latter proteins may be found in large EVs or indeed any EVs, but are expected to be less concentrated in the EV than in the cell.[37]

Biological functions of EVs

A wide variety of biological functions have been ascribed to EVs.

“Trash disposal”: eliminating unwanted materials
Transfer of functional proteins
Transfer of functional RNA
Molecular recycling or “nutrition”
Signaling to the recipient cell via cell-surface or endosomal receptors
Creation of a metastatic niche for cancer
Pathfinding through the environment
Quorum sensing
Mediating host-commensal or parasite/pathogen interaction

EVs as biomarkers and therapeutics

EVs in disease

EVs are believed to play a role in the spreading of different diseases. Studies have shown that tumor cells send EVs to send signal to target resident cells, which can lead to tumor invasion and metastasis[52].

In vitro studies of Alzheimer's disease have shown that astrocytes that accumulate amyloid beta release EVs that cause neuronal apoptosis[53]. The content of the EVs was also affected by the exposure to amyloid beta and higher ApoE was found in EVs secreted by astrocyte exposed to amyloid beta[54].

gollark: We don't live in one. Talking about one doesn't make it happen.
gollark: are you suggesting we stop free speech to get rid of an ideology you don't like, tronzoid?
gollark: Yes, bleach is indeed toxic.
gollark: This shouldn't be, and probably isn't, legal.
gollark: Dwarf Fortress will develop it in the ultimate episode of scope creep.

References
  1. Yáñez-Mó M, Siljander PR, Andreu Z, et al. (2015). "Biological properties of extracellular vesicles and their physiological functions". J Extracell Vesicles. 4: 27066. doi:10.3402/jev.v4.27066. PMC 4433489. PMID 25979354.
  2. CHARGAFF E, WEST R (November 1946). "The biological significance of the thromboplastic protein of blood". J. Biol. Chem. 166 (1): 189–97. PMID 20273687.
  3. Wolf P (May 1967). "The nature and significance of platelet products in human plasma". Br. J. Haematol. 13 (3): 269–88. doi:10.1111/j.1365-2141.1967.tb08741.x. PMID 6025241.
  4. Anderson HC (April 1969). "Vesicles associated with calcification in the matrix of epiphyseal cartilage". J. Cell Biol. 41 (1): 59–72. doi:10.1083/jcb.41.1.59. PMC 2107736. PMID 5775794.
  5. Bonucci E (1970). "Fine structure and histochemistry of "calcifying globules" in epiphyseal cartilage". Z Zellforsch Mikrosk Anat. 103 (2): 192–217. doi:10.1007/BF00337312. PMID 5412827.
  6. Nunez EA, Wallis J, Gershon MD (October 1974). "Secretory processes in follicular cells of the bat thyroid. 3. The occurrence of extracellular vesicles and colloid droplets during arousal from hibernation". Am. J. Anat. 141 (2): 179–201. doi:10.1002/aja.1001410203. PMID 4415703.
  7. Chandler RL, Bird RG, Bland AP (November 1975). "Letter: Particles associated with microvillous border of intestinal mucosa". Lancet. 2 (7941): 931–2. doi:10.1016/s0140-6736(75)92175-3. PMID 53415.}
  8. De Broe M, Wieme R, Roels F (December 1975). "Letter: Membrane fragments with koinozymic properties released from villous adenoma of the rectum". Lancet. 2 (7946): 1214–5. doi:10.1016/s0140-6736(75)92709-9. PMID 53703.
  9. Benz EW, Moses HL (June 1974). "Small, virus-like particles detected in bovine sera by electron microscopy". J. Natl. Cancer Inst. 52 (6): 1931–4. doi:10.1093/jnci/52.6.1931. PMID 4834422.
  10. Dalton AJ (May 1975). "Microvesicles and vesicles of multivesicular bodies versus "virus-like" particles". J. Natl. Cancer Inst. 54 (5): 1137–48. doi:10.1093/jnci/54.5.1137. PMID 165305.
  11. Pan BT, Johnstone RM (July 1983). "Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor". Cell. 33 (3): 967–78. doi:10.1016/0092-8674(83)90040-5. PMID 6307529.
  12. Harding C, Heuser J, Stahl P (November 1984). "Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding". Eur. J. Cell Biol. 35 (2): 256–63. PMID 6151502.
  13. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (July 1987). "Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)". J. Biol. Chem. 262 (19): 9412–20. PMID 3597417.
  14. Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, Carvalho AC (May 1981). "Tumor shedding and coagulation". Science. 212 (4497): 923–4. Bibcode:1981Sci...212..923D. doi:10.1126/science.7195067. PMID 7195067.
  15. Fox AS, Yoon SB (November 1970). "DNA-induced transformation in Drosophila: locus-specificity and the establishment of transformed stocks". Proc. Natl. Acad. Sci. U.S.A. 67 (3): 1608–15. Bibcode:1970PNAS...67.1608F. doi:10.1073/pnas.67.3.1608. PMC 283397. PMID 5274483.
  16. Mishra NC, Tatum EL (December 1973). "Non-Mendelian inheritance of DNA-induced inositol independence in Neurospora". Proc. Natl. Acad. Sci. U.S.A. 70 (12): 3875–9. Bibcode:1973PNAS...70.3875M. doi:10.1073/pnas.70.12.3875. PMC 427348. PMID 4521213.
  17. Stegmayr B, Ronquist G (1982). "Promotive effect on human sperm progressive motility by prostasomes". Urol. Res. 10 (5): 253–7. doi:10.1007/bf00255932. PMID 6219486.}
  18. Raposo G, Nijman HW, Stoorvogel W, et al. (March 1996). "B lymphocytes secrete antigen-presenting vesicles". J. Exp. Med. 183 (3): 1161–72. doi:10.1084/jem.183.3.1161. PMC 2192324. PMID 8642258.
  19. Mack, M.; Kleinschmidt, A.; et al. (2000). "Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection". Nature Medicine. 6 (7): 769–75. doi:10.1038/77498. PMID 10888925.
  20. Rozmyslowicz T, Majka M, Kijowski J, et al. (January 2003). "Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV". AIDS. 17 (1): 33–42. doi:10.1097/00002030-200301030-00006. PMID 12478067.
  21. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. (July 2006). "Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes". Cancer Immunol. Immunother. 55 (7): 808–18. doi:10.1007/s00262-005-0075-9. PMID 16283305.
  22. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ (September 2006). "Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication". Leukemia. 20 (9): 1487–95. doi:10.1038/sj.leu.2404296. PMID 16791265.
  23. Aliotta JM, Sanchez-Guijo FM, Dooner GJ, et al. (September 2007). "Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation". Stem Cells. 25 (9): 2245–56. doi:10.1634/stemcells.2007-0128. PMC 3376082. PMID 17556595.
  24. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (June 2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells". Nat. Cell Biol. 9 (6): 654–9. doi:10.1038/ncb1596. PMID 17486113.
  25. Skog J, Würdinger T, van Rijn S, et al. (December 2008). "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers". Nat. Cell Biol. 10 (12): 1470–6. doi:10.1038/ncb1800. PMC 3423894. PMID 19011622.
  26. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. (April 2010). "Functional delivery of viral miRNAs via exosomes". Proc. Natl. Acad. Sci. U.S.A. 107 (14): 6328–33. Bibcode:2010PNAS..107.6328P. doi:10.1073/pnas.0914843107. PMC 2851954. PMID 20304794.
  27. Al-Nedawi K, Meehan B, Rak J (July 2009). "Microvesicles: messengers and mediators of tumor progression". Cell Cycle. 8 (13): 2014–8. doi:10.4161/cc.8.13.8988. PMID 19535896.
  28. Hoshino, A.; Costa-Silva, B.; et al. (2015). "Tumour exosome integrins determine organotropic metastasis". Nature. 527 (7578): 329–35. Bibcode:2015Natur.527..329H. doi:10.1038/nature15756. PMC 4788391. PMID 26524530.
  29. Peinado H, Alečković M, Lavotshkin S, et al. (June 2012). "Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET". Nat. Med. 18 (6): 883–91. doi:10.1038/nm.2753. PMC 3645291. PMID 22635005.
  30. Melo SA, Sugimoto H, O'Connell JT, et al. (November 2014). "Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis". Cancer Cell. 26 (5): 707–21. doi:10.1016/j.ccell.2014.09.005. PMC 4254633. PMID 25446899.
  31. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R (June 2017). "Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer". Nature. 546 (7659): 498–503. Bibcode:2017Natur.546..498K. doi:10.1038/nature22341. PMC 5538883. PMID 28607485.
  32. Ostrowski M, Carmo NB, Krumeich S, et al. (January 2010). "Rab27a and Rab27b control different steps of the exosome secretion pathway". Nat. Cell Biol. 12 (1): 19–30, sup pp 1–13. doi:10.1038/ncb2000. hdl:10044/1/19574. PMID 19966785.
  33. van Niel G, Porto-Carreiro I, Simoes S, Raposo G (July 2006). "Exosomes: a common pathway for a specialized function". J. Biochem. 140 (1): 13–21. doi:10.1093/jb/mvj128. PMID 16877764. S2CID 43541754.
  34. Kowal J, Arras G, Colombo M, et al. (February 2016). "Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes". Proc. Natl. Acad. Sci. U.S.A. 113 (8): E968–77. Bibcode:2016PNAS..113E.968K. doi:10.1073/pnas.1521230113. PMC 4776515. PMID 26858453.
  35. Tkach M, Kowal J, Théry C (January 2018). "Why the need and how to approach the functional diversity of extracellular vesicles". Philos. Trans. R. Soc. Lond., B, Biol. Sci. 373 (1737): 20160479. doi:10.1098/rstb.2016.0479. PMC 5717434. PMID 29158309.}
  36. Leslie M (August 2013). "Cell Biology. NIH effort gambles on mysterious extracellular RNAs". Science. 341 (6149): 947. doi:10.1126/science.341.6149.947. PMID 23990535.
  37. Théry C, Witwer KW, Aikawa E, et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". J Extracell Vesicles. 7 (1): 1535750. doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  38. Trams EG, Lauter CJ, Salem N, Heine U (July 1981). "Exfoliation of membrane ecto-enzymes in the form of micro-vesicles". Biochim. Biophys. Acta. 645 (1): 63–70. doi:10.1016/0005-2736(81)90512-5. PMID 6266476.
  39. Morello M, Minciacchi VR, de Candia P, et al. (November 2013). "Large oncosomes mediate intercellular transfer of functional microRNA". Cell Cycle. 12 (22): 3526–36. doi:10.4161/cc.26539. PMC 3906338. PMID 24091630.
  40. Meehan B, Rak J, Di Vizio D (2016). "Oncosomes - large and small: what are they, where they came from?". J Extracell Vesicles. 5: 33109. doi:10.3402/jev.v5.33109. PMC 5040817. PMID 27680302.
  41. Melentijevic I, Toth ML, Arnold ML, et al. (February 2017). "C. elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress". Nature. 542 (7641): 367–371. Bibcode:2017Natur.542..367M. doi:10.1038/nature21362. PMC 5336134. PMID 28178240.
  42. Nolte-'t Hoen E, Cremer T, Gallo RC, Margolis LB (August 2016). "Extracellular vesicles and viruses: Are they close relatives?". Proc. Natl. Acad. Sci. U.S.A. 113 (33): 9155–61. doi:10.1073/pnas.1605146113. PMC 4995926. PMID 27432966.
  43. Zhang H, Freitas D, Kim HS, et al. (March 2018). "Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation". Nat. Cell Biol. 20 (3): 332–343. doi:10.1038/s41556-018-0040-4. PMC 5931706. PMID 29459780.
  44. Multia E, Tear CJ, Palviainen M, et al. (December 2019). "Fast isolation of highly specific population of platelet-derived extracellular vesicles from blood plasma by affinity monolithic column, immobilized with anti-human CD61 antibody". Analytica Chimica Acta. 1091: 160–168. doi:10.1016/j.aca.2019.09.022. PMID 31679569.
  45. Mateescu B, Kowal EJ, van Balkom BW, et al. (2017). "Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper". J Extracell Vesicles. 6 (1): 1286095. doi:10.1080/20013078.2017.1286095. PMC 5345583. PMID 28326170.
  46. Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J, Dignat-George F (March 2012). "Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol". J. Thromb. Haemost. 10 (3): 437–46. doi:10.1111/j.1538-7836.2011.04610.x. PMID 22212198.
  47. Witwer KW, Buzás EI, Bemis LT, et al. (2013). "Standardization of sample collection, isolation and analysis methods in extracellular vesicle research". J Extracell Vesicles. 2: 20360. doi:10.3402/jev.v2i0.20360. PMC 3760646. PMID 24009894.
  48. Coumans, F. A.; Brisson, A. R.; et al. (2017). "Methodological guidelines to study extracellular vesicles". Circulation Research. 120 (10): 1632–1648. doi:10.1161/CIRCRESAHA.117.309417. PMID 28495994.
  49. Lötvall J, Hill AF, Hochberg F, et al. (2014). "Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles". J Extracell Vesicles. 3: 26913. doi:10.3402/jev.v3.26913. PMC 4275645. PMID 25536934.
  50. Van Deun J, Mestdagh P, Agostinis P, et al. (February 2017). "EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research". Nat. Methods. 14 (3): 228–232. doi:10.1038/nmeth.4185. PMID 28245209.
  51. Dhondt, Bert; Geeurickx, Edward; Tulkens, Joeri; Van Deun, Jan; Vergauwen, Glenn; Lippens, Lien; Miinalainen, Ilkka; Rappu, Pekka; Heino, Jyrki; Ost, Piet; Lumen, Nicolaas; De Wever, Olivier; Hendrix, An (11 March 2020). "Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine". Journal of Extracellular Vesicles. 9 (1): 1736935. doi:10.1080/20013078.2020.1736935. PMC 7144211. PMID 32284825.
  52. Cappariello, Alfredo; Rucci, Nadia (2019-09-27). "Tumour-Derived Extracellular Vesicles (EVs): A Dangerous "Message in A Bottle" for Bone". International Journal of Molecular Sciences. 20 (19): 4805. doi:10.3390/ijms20194805. ISSN 1422-0067. PMC 6802008. PMID 31569680.
  53. Söllvander, Sofia; Nikitidou, Elisabeth; Brolin, Robin; Söderberg, Linda; Sehlin, Dag; Lannfelt, Lars; Erlandsson, Anna (12 May 2016). "Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons". Molecular Neurodegeneration. 11 (1): 38. doi:10.1186/s13024-016-0098-z. ISSN 1750-1326. PMC 4865996. PMID 27176225.
  54. Nikitidou, Elisabeth; Khoonsari, Payam Emami; Shevchenko, Ganna; Ingelsson, Martin; Kultima, Kim; Erlandsson, Anna (2017). "Increased Release of Apolipoprotein E in Extracellular Vesicles Following Amyloid-β Protofibril Exposure of Neuroglial Co-Cultures". Journal of Alzheimer's Disease. 60 (1): 305–321. doi:10.3233/JAD-170278. ISSN 1875-8908. PMC 5676865. PMID 28826183.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.